You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: What Should You Know?

  • Authors: Peter Schmid, MD, PhD, FRCP
  • CME / ABIM MOC Released: 11/12/2019
  • Valid for credit through: 11/12/2020
Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of oncologists, obstetricians & gynecologists, and surgeons.

The goal of this activity is to increase understanding of the use of checkpoint inhibition in triple-negative breast cancer (TNBC) in the metastatic and neoadjuvant settings.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trials studying the use of immune checkpoint inhibitors in patients with TNBC in the neoadjuvant and metastatic settings
    • How to identify which patients with TNBC may benefit from use of immune checkpoint inhibitors


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Peter Schmid, MD, PhD, FRCP

    Lead, Centre for Experimental Cancer Medicine
    Barts Cancer Institute, St Bartholomew’s Hospital
    Queen Mary University of London
    London, United Kingdom


    Disclosure: Peter Schmid, MD, PhD, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eisai Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma; Roche
    Received grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Oncogenex; Roche
    Other: Spouse: Genentech, Inc.; Roche


  • Charlotte Warren

    Senior Medical Education Director, Medscape, LLC


    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

  • Zach Hartman, PhD

    Scientific Content Manager, Medscape, LLC


    Disclosure: Zach Hartman, PhD has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements


In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: What Should You Know?





Educational Impact Challenge

What did you learn from this activity? Please answer the following question.

  • Print